CLDN18.2-positive advanced biliary tract cancer

Clinical trials for CLDN18.2-positive advanced biliary tract cancer explained in plain language.

Never miss a new study

Get alerted when new CLDN18.2-positive advanced biliary tract cancer trials appear

Sign up with your email to follow new studies for CLDN18.2-positive advanced biliary tract cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

New hope for bile duct cancer: experimental drug combo enters Mid-Stage trial

Disease control Not yet recruiting

This Phase II trial tests an experimental drug called QLS31905 combined with chemotherapy, with or without another drug (QL2107), in 120 people with advanced biliary tract cancer that has a specific protein (CLDN18.2). The goal is to see if the combination shrinks tumors. Partici…

Matched conditions: CLDN18.2-POSITIVE ADVANCED BILIARY TRACT CANCER

Phase 2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 26, 2026 12:50 UTC

CLDN18.2-positive advanced biliary tract cancer

Get alerted when new CLDN18.2-positive advanced biliary tract cancer trials appear

New hope for bile duct cancer: experimental drug combo enters Mid-Stage trial